Nexeon Medsystems (OTCMKTS: NXNND) is one of 47 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its rivals? We will compare Nexeon Medsystems to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, dividends, earnings, profitability and valuation.
Insider and Institutional Ownership
43.7% of shares of all “Electromedical equipment” companies are owned by institutional investors. 61.2% of Nexeon Medsystems shares are owned by company insiders. Comparatively, 15.5% of shares of all “Electromedical equipment” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Nexeon Medsystems and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Nexeon Medsystems Competitors||$1.25 billion||$101.33 million||-19.34|
Nexeon Medsystems’ rivals have higher revenue and earnings than Nexeon Medsystems.
This table compares Nexeon Medsystems and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Nexeon Medsystems Competitors||-130.47%||-69.88%||-20.69%|
This is a breakdown of recent ratings and price targets for Nexeon Medsystems and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Nexeon Medsystems Competitors||187||541||1115||45||2.54|
As a group, “Electromedical equipment” companies have a potential upside of 17.98%. Given Nexeon Medsystems’ rivals higher probable upside, analysts plainly believe Nexeon Medsystems has less favorable growth aspects than its rivals.
Nexeon Medsystems beats its rivals on 4 of the 7 factors compared.
About Nexeon Medsystems
Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.
Receive News & Ratings for Nexeon Medsystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexeon Medsystems and related companies with MarketBeat.com's FREE daily email newsletter.